Shulin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shulin Li has a total of 346 co-authors. Here are the top co-authors by number of shared publications:
Xueqing Xia
Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, USA
54 shared publicationsJiemiao Hu
24 shared publicationsAbhisek Mitra
Department of Pediatrics The University of Texas MD Anderson Cancer Center Houston Texas USA
15 shared publicationsJun Yan
Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China
15 shared publications- Amy B. Heimberger
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University , Chicago, Illinois
12 shared publications Arun Satelli
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
12 shared publications
Latest Publications
- Open Access
- 9 December 2025
- Published by Elsevier in Cancer Letters
- Vol. 640, 218215
Fgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges
- 9 December 2025
- Published by Elsevier in Cancer Letters
- Vol. 640, 218215
Open AccessFgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges
- Open Access
- 6 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (41)
Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas
Tumor-targeted T cell therapies of various types have been booming, but T cell therapy is limited by its inability to penetrate the collagen barrier surrounding tumors. The destruction of tumor collagen is significant because collagen both suppresses T cells and contributes to the formation of the extracellular matrix. Our previously reported cell-surface vimentin (CSV)–targeted and membrane-anchored interleukin 12-armed (attIL12) T cells can reduce collagen production by killing cancer-associated fibroblasts, but fail to reduce collagen expression by tumor cells, resulting in resistance to attIL12-T cell treatment. In this study, we found that CCKAR directly boosts collagen production by tumor cells in vitro and in vivo. attIL12-modified tumor-infiltrating lymphocytes (TILs) disabled collagen production by CCKAR-high autologous tumor cells in vitro and sarcoma patient-derived xenografts (PDXs) in vivo. This disruption of collagen production by tumor cells by attIL12-TILs overcomes resistance to attIL12-T cell treatment and required a simultaneous interaction between the CSV on autologous tumor cells, which is targeted by attIL12, and human leukocyte antigen-T cell receptor on attIL12-TILs; When either interaction was abrogated, collagen production and CCKAR expression were not shut down. Mechanistically, the interaction between attIL12-TILs and autologous tumor cells induced interferon gamma production synergistically, which in combination with CCKAR downregulation reduced collagen expression through suppression of both transforminggrowth factor beta-stimulated SMAD activation and CCKAR-AKT signaling. Diminishing collagen expression from tumor cells significantly increased T cell infiltration and improved tumor growth inhibition in PDX sarcomas. Thus, this attIL12-TIL therapy holds great clinical potential for boosting T cell infiltration in high-grade, collagen-rich tumors.
- 6 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (41)
Open AccessCollagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas
Tumor-targeted T cell therapies of various types have been booming, but T cell therapy is limited by its inability to penetrate the collagen barrier surrounding tumors. The destruction of tumor collagen is significant because collagen both suppresses T cells and contributes to the formation of the extracellular matrix. Our previously reported cell-surface vimentin (CSV)–targeted and membrane-anchored interleukin 12-armed (attIL12) T cells can reduce collagen production by killing cancer-associated fibroblasts, but fail to reduce collagen expression by tumor cells, resulting in resistance to attIL12-T cell treatment. In this study, we found that CCKAR directly boosts collagen production by tumor cells in vitro and in vivo. attIL12-modified tumor-infiltrating lymphocytes (TILs) disabled collagen production by CCKAR-high autologous tumor cells in vitro and sarcoma patient-derived xenografts (PDXs) in vivo. This disruption of collagen production by tumor cells by attIL12-TILs overcomes resistance to attIL12-T cell treatment and required a simultaneous interaction between the CSV on autologous tumor cells, which is targeted by attIL12, and human leukocyte antigen-T cell receptor on attIL12-TILs; When either interaction was abrogated, collagen production and CCKAR expression were not shut down. Mechanistically, the interaction between attIL12-TILs and autologous tumor cells induced interferon gamma production synergistically, which in combination with CCKAR downregulation reduced collagen expression through suppression of both transforminggrowth factor beta-stimulated SMAD activation and CCKAR-AKT signaling. Diminishing collagen expression from tumor cells significantly increased T cell infiltration and improved tumor growth inhibition in PDX sarcomas. Thus, this attIL12-TIL therapy holds great clinical potential for boosting T cell infiltration in high-grade, collagen-rich tumors.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Reverse expression patterns of CARM1 and MAP2K4 in breast cancer subtypes and CARM1-mediated MAP2K4 methylation potentiates the downstream JNK activation
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Reverse expression patterns of CARM1 and MAP2K4 in breast cancer subtypes and CARM1-mediated MAP2K4 methylation potentiates the downstream JNK activation
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Raw RPPA data, related to Figure 1
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Raw RPPA data, related to Figure 1
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Methylation of MAP2K4 promotes MDA-MB-468 cell proliferation and migration
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Methylation of MAP2K4 promotes MDA-MB-468 cell proliferation and migration
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki elicited a synergistic anti-growth effect MDA-MB-231, SUM159 and Cal-51 TNBC cell lines
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki elicited a synergistic anti-growth effect MDA-MB-231, SUM159 and Cal-51 TNBC cell lines
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Subcellular localization of CARM1, total MAP2K4 and me-MAP2K4 in MDA-MB-231 and Cal-51 parental cells and the corresponding CARM1KO cells.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Subcellular localization of CARM1, total MAP2K4 and me-MAP2K4 in MDA-MB-231 and Cal-51 parental cells and the corresponding CARM1KO cells.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Treatment with EZM2302 increases CARM1 and PRMT1 levels, and the list of proteins affected by BKM120, TP-064, or both, and the basal AKT activation status in various breast cancer cell lines.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
Treatment with EZM2302 increases CARM1 and PRMT1 levels, and the list of proteins affected by BKM120, TP-064, or both, and the basal AKT activation status in various breast cancer cell lines.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
The list of proteins whose levels are affected by treatment with TP-064, BKM120, or both in Fig. 1B.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
The list of proteins whose levels are affected by treatment with TP-064, BKM120, or both in Fig. 1B.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki synergistically inhibit the growth of a patient-derived xenograft organoid (PDxO)
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1i and PI3Ki synergistically inhibit the growth of a patient-derived xenograft organoid (PDxO)